301 related articles for article (PubMed ID: 15492926)
1. CYP3A variation and the evolution of salt-sensitivity variants.
Thompson EE; Kuttab-Boulos H; Witonsky D; Yang L; Roe BA; Di Rienzo A
Am J Hum Genet; 2004 Dec; 75(6):1059-69. PubMed ID: 15492926
[TBL] [Abstract][Full Text] [Related]
2. Sequence diversity and haplotype structure at the human CYP3A cluster.
Thompson EE; Kuttab-Boulos H; Yang L; Roe BA; Di Rienzo A
Pharmacogenomics J; 2006; 6(2):105-14. PubMed ID: 16314882
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
7. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.
Miao J; Jin Y; Marunde RL; Gorski CJ; Kim S; Quinney S; Radovich M; Li L; Hall SD
Pharmacogenomics J; 2009 Oct; 9(5):319-26. PubMed ID: 19506580
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 genetic polymorphisms in different ethnic populations.
Roy JN; Lajoie J; Zijenah LS; Barama A; Poirier C; Ward BJ; Roger M
Drug Metab Dispos; 2005 Jul; 33(7):884-7. PubMed ID: 15833928
[TBL] [Abstract][Full Text] [Related]
9. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
11. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine.
Chen X; Wang H; Zhou G; Zhang X; Dong X; Zhi L; Jin L; He F
Environ Health Perspect; 2009 Oct; 117(10):1541-8. PubMed ID: 20019904
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
13. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
[TBL] [Abstract][Full Text] [Related]
14. The genetic determinants of the CYP3A5 polymorphism.
Hustert E; Haberl M; Burk O; Wolbold R; He YQ; Klein K; Nuessler AC; Neuhaus P; Klattig J; Eiselt R; Koch I; Zibat A; Brockmöller J; Halpert JR; Zanger UM; Wojnowski L
Pharmacogenetics; 2001 Dec; 11(9):773-9. PubMed ID: 11740341
[TBL] [Abstract][Full Text] [Related]
15. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
16. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
17. Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individuals.
Nakamura T; Saito Y; Murayama N; Saeki M; Soyama A; Sai K; Ozawa S; Sawada J
Biol Pharm Bull; 2001 Aug; 24(8):954-7. PubMed ID: 11510493
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.
Park SY; Kang YS; Jeong MS; Yoon HK; Han KO
J Clin Pharm Ther; 2008 Feb; 33(1):61-5. PubMed ID: 18211618
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.
Solus JF; Arietta BJ; Harris JR; Sexton DP; Steward JQ; McMunn C; Ihrie P; Mehall JM; Edwards TL; Dawson EP
Pharmacogenomics; 2004 Oct; 5(7):895-931. PubMed ID: 15469410
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 variant allele frequencies in Dutch Caucasians.
van Schaik RH; van der Heiden IP; van den Anker JN; Lindemans J
Clin Chem; 2002 Oct; 48(10):1668-71. PubMed ID: 12324482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
